Legal Challenges and Pharmaceutical Innovations: Health News Digest

A Florida lawsuit claims Campbell's SpaghettiOs were contaminated with worms. The U.S. Supreme Court supports Hikma in a patent case, influencing generic drug patents. Parabilis Medicines plans a $475 million IPO. Roche criticizes U.S. tariffs. Kenyan President supports a U.S. Ebola facility. Abbott faces a lawsuit over PediaSure claims.

A Florida family has filed a lawsuit against Campbell's, alleging contamination of SpaghettiOs with worms, which they found unfit for consumption. Mary Hubbard, the complainant, discovered the issue when she and her daughter began eating the product at their Okeechobee County home.

The U.S. Supreme Court has ruled in favor of Hikma Pharmaceuticals regarding a 'skinny label' patent case. Hikma's generic cardiovascular medication was not found to infringe on Amarin Pharma's patents, a decision which could positively impact generic drugmakers and potentially reduce drug prices across the U.S.

Biopharmaceutical firm Parabilis Medicines aims to raise up to $475 million through a U.S. IPO, thanking a resurgence in the summer IPO market for encouraging more companies to test investor appetite. This comes amidst a flurry of well-received market listings sparking renewed investor interest.